Pasithea Therapeutics Corp. Warrants (KTTAW) Stock Price
KTTAWStock
$0.01
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.21
KTTAW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-56.83%
Price vs S&P 500 (4W)-26.76%
VGM Score40.15
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KTTAWPasithea Therapeutics Corp. Warrants | — | — | C | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Pasithea Therapeutics Corp. Warrants
Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders, RASopathies, and select cancers. Its pipeline targets neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, and schizophrenia, with lead candidates including PAS-004 (a MEK1/2 inhibitor), PAS-003 (a monoclonal antibody), and PAS-001.